Florricks Lifecare, a research-driven global pharmaceutical company known for its R&D, production, and sales of active pharmaceutical ingredients (API) and finished dosage forms across multiple therapeutic areas, including critical care and oncology, has entered into strategic partnerships with two prominent companies in Hong Kong and Europe, marking a total investment of US$ 95 million.
This strategic move, the company says, is poised to enhance Florricks Lifecare’s global footprint, driving innovation and growth in the pharmaceutical industry. The partnerships aim to leverage Florricks Lifecare’s expertise in pharmaceutical solutions, bolstering its presence and capabilities in these critical regions.
Dr Salim Shaikh, managing director & CEO of Florricks Lifecare, stated, “This collaboration represents a pivotal moment for our company as we expand our global reach and strengthen our commitment to delivering high-quality pharmaceutical products. The investment underscores our dedication to innovation and excellence in the healthcare sector. Florricks Lifecare continues to lead the way in developing advanced pharmaceutical solutions for the evolving needs of patients and healthcare professionals worldwide. With this investment, the company is set to make substantial strides in research, development, and production, ensuring the highest standards of quality and safety.”
Established with a vision to make a difference in healthcare, Florricks Lifecare has grown to become a recognized leader in sourcing and supplying APIs and intermediates to pharmaceutical manufacturers and healthcare providers worldwide, Shaikh said.
Lalit Singh, executive director of Florricks Lifecare, said Florricks Lifecare’s hybrid supplying and global sourcing model for ingredients and raw materials delivers the most flexible and reliable solutions for its customers’ manufacturing requirements. “We offer the flexibility to supply or source difficult-to-find ingredients and materials, supported by industry-leading standards of quality documentation and regulatory compliance. This investment will propel Florricks Lifecare to further expand our global expansion.”
Florricks Lifecare, headquartered in Mumbai, is a global player in the pharmaceutical industry with a widespread international presence. It specializes in a range of products, including pharmaceutical APIs, finished formulations, critical raw materials, advanced intermediates, impurities, pellets, and nutraceuticals. It has a presence in over 45 countries across Asia, Europe, Africa, North America, and South America.
